From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine
about
Immunological Evaluation of Recent MUC1 Glycopeptide Cancer VaccinesDysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic AgentsStrategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen ModificationGlycotherapy: new advances inspire a reemergence of glycans in medicineCancer vaccines and carbohydrate epitopes.Human Cancer Antigen Globo H Is a Cell-Surface Ligand for Human Ribonuclease 1.Solving the convergence problem in the synthesis of triantennary N-glycan relevant to prostate-specific membrane antigen (PSMA).Immunologic mapping of glycomes: implications for cancer diagnosis and therapyA Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First RemissionNatural and Induced Humoral Responses to MUC1.A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinicSynthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience.Synthesis of the tumor associative α-aminooxy disaccharide of the TF antigen and its conjugation to a polysaccharide immune stimulant.The promise of glycomics, glycan arrays and carbohydrate-based vaccines.Carbohydrate-based vaccines: challenges and opportunities.Carbohydrate chemistry in drug discovery.Toward automated oligosaccharide synthesis.Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies.The sweet side of tumor immunotherapy.Multivalent glyco(cyclo)peptides.Recent progress in the field of neoglycoconjugate chemistry.Recent Developments in Synthetic Carbohydrate-Based Diagnostics, Vaccines, and Therapeutics.Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression.Synthetically defined glycoprotein vaccines: current status and future directions.Immunological evaluation of the entirely carbohydrate-based Thomsen-Friedenreich - PS B conjugate.Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine.Affinity of monoclonal antibodies for Globo-series glycansRecent progress in antitumoral synthetic vaccines.One-pot multi-enzyme (OPME) chemoenzymatic synthesis of sialyl-Tn-MUC1 and sialyl-T-MUC1 glycopeptides containing natural or non-natural sialic acid.Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines.Immune activation with peptide assemblies carrying Lewis y tumor-associated carbohydrate antigen.Chemoenzymatic synthesis of neoglycoproteins driven by the assessment of protein surface reactivity
P2860
Q26740513-EC47F716-7D48-42A3-9575-5A6BE49F8A58Q26771367-8EE6DAD1-885C-48A9-AD4E-801847943803Q27001592-7CE6715D-62AA-4F11-A8DB-2F5C893F503CQ27027997-10E760D4-1ECF-4094-9DED-0AD986B9AE29Q35525289-57A4157E-BAE4-4001-9623-6BB62FA8CBB4Q36063340-EE384430-4B95-4A7F-A0DC-27496B6E9175Q36313627-24BBB90D-3E49-42EB-88FD-FC9E10B01C5CQ36543504-05C6F7AD-3BA4-49B6-B29F-E659BFE121D5Q36841027-769374F6-1759-4348-963E-6BE909264D06Q37137385-51191020-1A01-4550-B352-858DE7163D50Q37303845-48688914-CCE3-44F8-86BE-443B9F67D921Q37608314-4D8D9D78-BE0A-4DFB-9430-282E82FBA94DQ37642032-BE7535BE-D6DB-4FBC-A4B1-98B1DC5F3D94Q37689188-0031A38F-1189-4BFD-BB17-78CD6377284BQ37810597-719B99F6-B872-43ED-BAE8-65DB41A719EEQ37853437-42427DD0-C7B1-4946-B72F-B42F3DC248E3Q37962848-05FE6B5B-4CC6-4CBA-B12B-F84FA4F76AD9Q37993590-1C860B06-C4BA-4B77-BC48-62E46F70A73CQ38031282-96831E54-8560-4767-94F4-11FA4A848775Q38069441-D27962BE-CE70-4061-8D53-29F9249EC11DQ38472393-B5372318-2E23-4BF5-A8CE-9CF2EB92C020Q38533442-C5595366-76B5-48AD-B506-0122709C00C5Q39079672-DFD0C2EC-55A1-4367-81AF-1A9F5C7B438FQ39375701-3B69A2C5-718D-4863-80E4-D8EC9506A263Q39935587-430485C0-AE77-4AFF-8A40-72B4A540B316Q41194257-75CEA75A-F075-4DD1-9C3D-B8B103655907Q42149743-2B64A276-1483-439D-9332-FD204EF14175Q43007810-0FFA1023-5415-417D-8462-A478BEB129B3Q43076252-DDDCF93A-777B-4560-B453-8A7D05094796Q48169265-6B98CA69-F761-487C-928B-05ACDA05B0FAQ51141205-4F2E8877-89C1-494B-8000-F1EB9AB4C37DQ56036811-5FA634AF-304B-4A60-AB1D-C7ABECE3C7CF
P2860
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine
@ast
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine
@en
type
label
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine
@ast
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine
@en
prefLabel
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine
@ast
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine
@en
P2093
P2860
P356
P1476
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine
@en
P2093
Dongjoo Lee
Govind Ragupathi
Guangbin Yang
Jianglong Zhu
Maria K Spassova
Payal Damani
Philip O Livingston
Samuel J Danishefsky
P2860
P304
P356
10.1021/JA901415S
P407
P577
2009-07-01T00:00:00Z